Iboga, ibogaine, noribogaine & 18-MC



Jump to:



Maas & Strubelt (2006). Fatalities after taking ibogaine in addiction treatment could be related to sudden cardiac death caused by autonomic dysfunction. Medical Hypotheses.

Paskulin et al. (2006). Ibogaine affects brain energy metabolism. European Journal of Pharmacology.

Passarella et al. (2006). Nature-inspired indolyl-2-azabicyclo[2.2.2]oct-7-ene derivatives as promising agents for the attenuation of withdrawal symptoms: synthesis of 20-desethyl-20-hydroxymethyl-11-demethoxyibogaine. Natural Product Research.

Werneke, Turner & Priebe (2006). Complementary medicines in psychiatry: Review of effectiveness and safety. The British Journal of Psychiatry.

Jacobs et al. (2007). Ibogaine, a noncompetitive inhibitor of serotonin transport, acts by stabilizing the cytoplasm-facing state of the transporter. The Journal of Biological Chemistry.

Rieckmann et al. (2007). Client and counselor attitudes toward the use of medications for treatment of opioid dependence. Journal of Substance Abuse Treatment.

Taraschenko et al. (2007). 18-MC acts in the medial habenula and interpeduncular nucleus to attenuate dopamine sensitization to morphine in the nucleus accumbens. Synapse.

Alper, Lotsof & Kaplan (2008). The ibogaine medical subculture.

Chèze et al. (2008). Determination of ibogaine and noribogaine in biological fluids and hair by LC-MS/MS after Tabernanthe iboga abuse Iboga alkaloids distribution in a drowning death case. Forensic Science International.

Glick, Sell & Maisonneuve (2008). Brain regions mediating alpha3beta4 nicotinic antagonist effects of 18-MC on methamphetamine and sucrose self-administration. European Journal of Pharmacology.

Jarraya et al. (2008). N-(hydroxymethyl)ibogaine. Acta Crystallographica Section E-Structure Reports Online.

Jozwiak et al. (2008). Interaction of ibogaine analogs with the nicotinic acetylcholine receptor. FASEB Journal.

Kubiliene et al. (2008). Acute toxicity of ibogaine and noribogaine. Medicina.

Maciulaitis et al. (2008). Ibogaine, an anti-addictive drug: pharmacology and time to go further in development. A narrative review. Human & Experimental Toxicology.

Taraschenko et al. (2008). 18-Methoxycoronaridine: A potential new treatment for obesity in rats? Psychopharmacology.

Hoelen (2009). Long-QT syndrome induced by the antiaddiction drug ibogaine. New England Journal of Medicine.

McCallum & Glick (2009). 18-Methoxycoronaridine blocks acquisition but enhances reinstatement of a cocaine place preference. Neuroscience Letters.

Tournier et al. (2009). Ibogaine labeling with TC-99M-Tricarbonyl: synthesis and transport at the mouse blood-brain barrier. Journal of Pharmaceutical Sciences.

Arias et al. (2010). Interaction of ibogaine with human alpha 3 beta 4-nicotinic acetylcholine receptors in different conformational states. International Journal of Biochemistry & Cell Biology.

Carnicella et al. (2010). Noribogaine, but not 18-MC, exhibits similar actions as ibogaine on GDNF expression and ethanol self-administration. Addiction Biology.

Jana & Sinha (2010). A concise route to iboga-analogues via the formation of suitably substituted-2-indoles. Tetrahedron Letters.

Low et al. (2010). Structure, biological activity, and a biomimetic partial synthesis of the lirofolines, novel pentacylic indole alkaloids from Tabernaemontana. Tetrahedron Letters.

Pjevalica (2010). Meta-analysis: The effect of ibogaine and 18-methoxycoronaridine on dopamine levels in brain. European Journal of Medical Research.

Taraschenko, Maisonneuve & Glick (2010). 18-Methoxycoronaridine, a potential anti-obesity agent, does not produce a conditioned taste aversion in rats. Pharmacology, Biochemistry and Behavior.

Tournier et al. (2010). Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). International Journal of Neuropsychopharmacology.

Zhang et al. (2010). Ibogaine stimulates ionic currents mediated by serotonin transporter. Biophysical Journal.

Arias et al. (2011). Structure-activity relationship of ibogaine analogs interacting with nicotinic acetylcholine receptors in different conformational states. International Journal of Biochemistry & Cell Biology.

Binienda et al. (2011). Analysis of electrical brain waves in neurotoxicology: Gamma-hydroxybutyrate. Current Neuropharmacology.

Donnelly (2011). The need for ibogaine in drug and alcohol addiction treatment. Journal of Legal Medicine.

Galea et al. (2011). Ibogaine--be informed before you promote or prescribe. Journal of Primary Health Care.

Gevirtz (2011). Anesthesia for opiate detoxification and the ibogaine controversy. International Anesthesiology Clinics.

Glick et al. (2011). Brain regions mediating α3β4 nicotinic antagonist effects of 18-MC on nicotine self-administration. European Journal of Pharmacology.

Houenou et al. (2011). Ibogaine-associated psychosis in schizophrenia: A case report. Psychopharmacology.

McCallum et al. (2011). Effects of 18-methoxycoronaridine on ghrelin-induced increases in sucrose intake and accumbal dopamine overflow in female rats. Psychopharmacology.

Taraschenko, Maisonneuve & Glick (2011). Resistance of male Sprague–Dawley rats to sucrose-induced obesity: Effects of 18-methoxycoronaridine. Physiology & Behavior.

Taraschenko, Maisonneuve & Glick (2011). Sex differences in high fat-induced obesity in rats: Effects of 18-methoxycoronaridine. Physiology & Behavior.

Ward et al. (2011). Herbal medicines for the management of opioid addiction: Safe and effective alternatives to conventional pharmacotherapy? CNS Drugs.

Alper, Stajic & Gill (2012). Fatalities temporally associated with the ingestion of ibogaine. Journal of Forensic Sciences.

Alper, Reith & Sershen (2012). Ibogaine and the inhibition of acetylcholinesterase. Journal of Ethnopharmacology.

Bulling et al. (2012). The mechanistic basis for noncompetitive ibogaine inhibition of serotonin and dopamine transporters. Journal of Biological Chemistry.

Emert et al. (2012). Interaction of ibogaine with human a3b4 nicotinic receptors in different conformational states. FASEB Journal.

Jana & Sinha (2012). Total synthesis of ibogaine, epiibogaine and their analogues. Tetrahedron.

Paling et al. (2012). Life-threatening complications of ibogaine: three case reports. Netherlands Journal of Medicine.

Paškulin et al. (2012). Metabolic plasticity and the energy economizing effect of ibogaine, the principal alkaloid of Tabernanthe iboga. Journal of Ethnopharmacology.

Pleskovic et al. (2012). Ibogaine-associated ventricular tachyarrhythmias. Clinical Toxicology.

Polston et al. (2012). 18-Methoxycoronaridine blocks context-induced reinstatement following cocaine self-administration in rats. Pharmacology, Biochemistry and Behavior.

Shawn et al. (2012). Pause-dependent ventricular tachycardia and torsades de pointes after ibogaine ingestion. Clinical Toxicology.

Antonio (2013). Effect of iboga alkaloids on mu-opioid receptor-coupled G protein activation. PLoS ONE.

Asua (2013). Growing menace of ibogaine toxicity. British Journal of Anaesthesia.

Brown (2013). Ibogaine in the treatment of substance dependence. Current Drug Abuse Reviews.

Cachat (2013). Unique and potent effects of acute ibogaine on zebrafish: The developing utility of novel aquatic models for hallucinogenic drug research. Behavioural Brain Research.

Dettmer, Cohn & Schwarz (2013). Prolonged QTc and ventricular tachycardia after ibogaine ingestion. Clinical Toxicology.

Jalal, Daher & Hilu (2013). A case of death due to Ibogaine use for heroin addiction. The American Journal on Addictions.

Koenig et al. (2013). Anti-addiction drug ibogaine inhibits voltage-gated ionic currents: A study to assess the drug's cardiac ion channel profile. Toxicology and Applied Pharmacology.

Laes & Cole (2013). Cardiac manifestations during treatment with ibogaine. Clinical Toxicology.